NCT04489550 is a clinical trial in Middle Ear Cholesteatoma, sponsored by University Hospital, Montpellier.

Who is sponsoring NCT04489550?

NCT04489550 is sponsored by University Hospital, Montpellier.

What condition does NCT04489550 study?

NCT04489550 studies Middle Ear Cholesteatoma.

Is NCT04489550 still recruiting?

NCT04489550 is currently completed. Last updated 29 July 2020.

Last reviewed 2020-07-29 · How we verify

NCT04489550

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

How Long Must the MRI Follow-up Last to Safely Identify Middle Ear Residual Cholesteatoma

Completed Last updated 29 July 2020

What this trial tests

trial in Middle Ear Cholesteatoma in 17 participants. Completed in 31 December 2019.

Timeline

1 January 2013

Primary endpoint
1 December 2019

31 December 2019

Quick facts

Lead sponsor	University Hospital, Montpellier
Status	Completed
Study type	OBSERVATIONAL
Enrollment	17
Start date	1 January 2013
Primary completion	1 December 2019
Estimated completion	31 December 2019
Sites	1 location across France

Conditions studied

Middle Ear Cholesteatoma — all drugs for Middle Ear Cholesteatoma →

Sponsor

University Hospital, Montpellier

Who can join

Eligibility, any sex, with Middle Ear Cholesteatoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Previous studies demonstrated the high diagnostic value of non-echoplanar diffusion weighted magnetic resonance imaging (non-EP DWI) for residual cholesteatoma. However, limited data are available regarding a suitable length of imaging follow-up. The present study aimed to determine the optimal duration of non-EP DWI follow-up for residual cholesteatoma

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Montpellier trials

Trials by the same sponsor.

NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04489550 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
Last refreshed: 29 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04489550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing